Day: July 14, 2020

アンジェリーニ･ファーマは、EU、欧州経済地域諸国、およびスイス、トルコ、英国、ロシアにおいて、アンジェルマン症候群への治療効果を期待できるOV101 (ガボキサドール) の開発、製造、商品化の独占的な権利を取得オービッド･セラピューティクスは、前払い金の2,000万ドル (約21億4,000万円) に加え、開発、製造、販売のマイルストーンを達成した段階で最大2億1,250万ドル (約227億9,800万円)、さらに商品化に成功した場合に正味売上高に対して2桁のロイヤリティーを受け取ることになる アンジェリーニ･ファーマは、新しい関連会社のアンジェリーニ･ファーマ･レア･ディジーズAGを通じて契約を遂行 オービッドは、本日午前8時15分 (東部夏時間) に電話会議とウェブキャストを開催ニューヨークおよびローマ発, July 15, 2020 (GLOBE NEWSWIRE) — 神経系の希少疾患患者の生活向上をもたらす医薬品の開発に取り組むバイオ医薬品製造会社のオービッド･セラピューティクス (Ovid Therapeutics Inc.) (NASDAQ: OVID、以降「オービッド」) と、患者のためのメンタルヘルス、希少疾患、消費者の健康に幅広く取り組んでいるイタリアの家族経営の医薬品製造会社であるアンジェリーニ･ファーマ (Angelini Pharma S.p.A.、以降「アンジェリーニ･ファーマ」) は、アンジェリーニ･ファーマがEU、欧州経済地域諸国、およびスイス、トルコ、英国、ロシアにおいて、アンジェルマン症候群への治療効果を期待できるOV101 (ガボキサドール) の開発、製造、商品化を行う契約の締結を発表した。アンジェリーニ･ファーマは、新しい関連会社のアンジェリーニ･ファーマ･レア･ディジーズAGを通じて契約を遂行する。開発中のOV101は、唯一のデルタ (δ) 選択的GABAA受容体作用物質になると考えられている。現在は、アンジェルマン症候群の重要な第Ⅲ相NEPTUNE臨床試験による評価中で、2020年第4四半期にはトップライン結果の報告を予定している。契約条件に基づき、オービッドは前払い金の2,000万ドル...

Angelini Pharma는 유럽연합 및 기타 유럽경제지역 국가(스위스, 터키, 영국), 그리고 러시아에 공급될 수 있는 엔젤만증후군 치료용 OV101 (gaboxadol)의 독점적인 개발, 생산, 상용화 권한 획득Ovid Therapeutics에게는 2,000만 달러를 선급금으로 지급됨, 향후 초기 적응증(엔젤만증후군)과 관련된 개발과 생산, 판매 성과 달성에 따라 최대 2억 1,250만 달러를 추가로 지급하며 상용화에 성공할 경우 순매출액 대비 두자릿수 퍼센티지의 로열티 지급Angelini Pharma, 신규 자회사인 Angelini Pharma Rare Diseases AG를 통해 계약 이행Ovid, 미국동부시간 7월 13일 오전 8시 15분 컨퍼런스콜 및 웹캐스트 실시미국 뉴욕/이탈리아 로마, July 15, 2020 (GLOBE NEWSWIRE) — 희귀 신경질환 환자들의 삶의 질 향상을 위한 의약품 개발에 앞장 서고 있는 바이오 제약사인 Ovid Therapeutics Inc. (NASDAQ: OVID, 이하 “Ovid”)는 이탈리아 가족소유 제약사로 지속적이고 광범위한 형태로 정신 건강, 희귀병, 소비자 건강 분야에 초점을 두고 있는 Angelini Pharma S.p.A. (이하 “Angelini Pharma”)와 협약을 맺었다고 발표했다. 이에 따르면 Angelini Pharma는 유럽연합 및 기타 유럽경제지역 국가(스위스, 터키, 영국), 그리고 러시아에 공급될 수 있는 엔젤만증후군 치료용 OV101 (gaboxadol)의 개발, 생산, 상용화를 담당하게 된다. Angelini Pharma는 신규 자회사인 Angelini Pharma Rare Diseases...

Angelini Pharma mendapat hak pembangunan, pembuatan dan pemerdagangan yang eksklusif terhadap OV101 (gaboxadol) sebagai rawatan berpotensi untuk sindrom Angelman di Kesatuan Eropah dan negara lain di Kawasan Ekonomi Eropah, dan juga Switzerland, Turki, United Kingdom serta RusiaOvid Therapeutics akan menerima bayaran pendahuluan sebanyak $20 juta dan bayaran tambahan sehingga $212.5 juta selepas kemajuan pembangunan, pengeluaran dan jualan berjaya dicapai selain royalti dua digit pada jualan bersih jika berjaya diperdagangkan Angelini Pharma akan melaksanakan perjanjian melalui sekutu baharunya Angelini Pharma Rare Diseases AG Ovid bakal menganjurkan panggilan persidangan dan siar web hari ini pada 8:15 a.m. EDTNEW YORK dan ROME, July 15, 2020 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID, kemudian dari ini “Ovid”), sebuah...

A Angelini Pharma obtém os direitos exclusivos de desenvolvimento, fabricação e comercialização do OV101 (gaboxadol) para o potencial tratamento da síndrome de Angelman na União Europeia, outros países do Espaço Econômico Europeu, e também Suíça, Turquia e Reino Unido e RússiaA Ovid Therapeutics receberá um pagamento antecipado de 20 milhões de dólares, e pagamentos adicionais de até 212,5 milhões de dólares, após o desenvolvimento, produção e venda, incluindo royalties de dois dígitos sobre as vendas líquidas se comercializadas com sucesso A Angelini Pharma executará o acordo por meio de sua nova afiliada, a Angelini Pharma Rare Diseases AG A Ovid realizará uma teleconferência e webcast hoje às 8 h 15 EDTNOVA YORK e ROMA, July 14, 2020 (GLOBE NEWSWIRE) — A Ovid Therapeutics Inc. (NASDAQ: OVID, doravante “Ovid”), uma biofarmacêutica...

Angelini Pharma obtiene derechos exclusivos de desarrollo, fabricación y comercialización de OV101 (gaboxadol) para el tratamiento potencial del síndrome de Angelman en la Unión Europea y otros países en el Espacio Económico Europeo, y también Suiza, Turquía, el Reino Unido y Rusia.Ovid Therapeutics recibirá un pago por adelantado de $ 20 millones y pagos adicionales de hasta $ 212,5 cuando se alcancen las metas de desarrollo, fabricación y ventas, además de regalías de dos dígitos en las ventas netas, si se comercializa con éxito. Angelini Pharma celebrará el acuerdo a través de su nueva filial, Angelini Pharma Rare Diseases AG. Ovid celebrará una teleconferencia y transmisión vía web hoy a las 8:15 a. m. (hora de verano del este).NUEVA YORK y ROMA, July 15, 2020 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID, de aquí...

VANCOUVER, British Columbia, July 14, 2020 (GLOBE NEWSWIRE) — NexOptic Technology Corp. (“NexOptic” or the “Company”) (TSX VENTURE: NXO) (OTCQB: NXOPF) (FSE: E3O1), hereby provides notice that the 30-day accelerated exercise provision attached to NexOptic share purchase warrants that were approved for re-pricing from $0.60 to $0.36 in June of this year is now in effect. Warrant holders have until 4:00 PM PST (Vancouver time) on August 13, 2020 to exercise any outstanding warrants, after which the warrants will have expired and all unexercised warrants will be void and of no effect.Of 7,531,449 warrants in question, 2,924,949 (approximately 40%) have already been exercised for gross proceeds of $1,052,981.64 to the Company.In accordance with the policies of the TSXV Venture Exchange (“TSX-V”), upon a re-pricing of warrants...

CALGARY, Alberta, July 14, 2020 (GLOBE NEWSWIRE) — News Release – TC Energy Corporation (TSX, NYSE: TRP) (TC Energy) will hold a teleconference and webcast on Thursday, July 30, 2020 to discuss its second quarter financial results, which will be released pre-market.Russ Girling, TC Energy President and Chief Executive Officer, Don Marchand, Executive Vice-President, Strategy & Corporate Development and Chief Financial Officer, and other members of the executive leadership team will discuss the financial results and Company developments at 9 a.m. (MDT) / 11 a.m. (EDT).Members of the investment community and other interested parties are invited to participate by calling 1-855-327-6838. No pass code is required. Please dial in 15 minutes prior to the start of the call.  A live webcast of the teleconference will be available on...

TORONTO, July 14, 2020 (GLOBE NEWSWIRE) — iLOOKABOUT Corp. (TSXV:ILA; OTCQB:ILATF) (“ILA” or “the Company”) today announced that its Financial Statements for the three months ended March 31, 2020, and the related Management’s Discussion and Analysis (“MD&A”) are available at www.sedar.com and on the Company’s website at http://www.ilookabout.com/investor-relations/financial-information. Shareholders may request a hard copy of this material by directing their request to: iLOOKABOUT Corp., Office of the CFO, 408-383 Richmond Street, London ON, N6A 3C4.ILA entered 2020 with many growth initiatives underway. The Company was able to achieve 94% ($5.1M Q1 2020 vs $2.6M Q1 2019) revenue growth year-over-year, as a result of entering the US lending market. Unfortunately, like many other organizations globally, the Company is being...

SPOKANE VALLEY, Wash., July 14, 2020 (GLOBE NEWSWIRE) — Keytronic Corporation (Nasdaq KTCC), a world class provider of engineering design and electromechanical manufacturing services, today announced it has been selected by Manufacturing Technology Insights Magazine as a Top 10 Contract Manufacturing Service Provider for 2020.    “I’m very proud and excited to be selected as a 2020 Top 10 Contract Manufacturing Service Provider,” said Craig Gates, President and Chief Executive Officer.  “This award is validation of many years of hard work transitioning from an OEM manufacturer to a turnkey contract manufacturer.  Our unique ability to bring our perspective, experience and knowledge as a former OEM to our outsourcing OEM customers has been a significant factor in our success.  In addition, our flexibility, vertical integration and...

MARIETTA, Ga., July 14, 2020 (GLOBE NEWSWIRE) — BlueLinx Holdings Inc. (NYSE: BXC), a leading distributor of building and industrial products in the United States, will host a conference call and webcast to discuss the company’s second quarter results on Tuesday, August 4th,  at 10:00 a.m. Eastern Time.  The company’s press release announcing its financial results will be made available after the market closes on Monday, August 3rd, under Press Releases in the Investor Relations section of the BlueLinx website, at www.BlueLinxCo.com.During the call, Mitch Lewis, Chief Executive Officer, and Kelly Janzen, Chief Financial Officer and Treasurer, will discuss the company’s financial results for the second quarter. Participants can access the live conference call via telephone at (877) 873-5864, using Conference ID # 3795155. Investors...